The relationship between President Trump’s personal attorney, Michael Cohen, and Novartis was more extensive than the drug maker previously disclosed, and the company issued misleading statements about the relationship, according to a report issued by Senate Democrats on Friday.

Dozens of emails and other documents revealed that the agreement between Cohen and Novartis was longer and more detailed than had been previously stated. Moreover, Novartis explicitly sought to hire Cohen to gain access to “key policymakers” and provided him with ideas for lowering drug costs, which later appeared in the Trump administration blueprint that was developed to address the issue.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hopefully no one is too surprised. These corrupt corporations get what they pay for. No one seems to be paying attention to the uptick in Pharma advertising, including Advertorials in major media. It looks like Pharma now owns our regulatory boards, and our mass media. This is what a “Market Driven” healthcare industry looks like. The negative outcomes are just bad for business, or as they put it at the industry funded meetings, could lead to “liability.”

  • Hello Christopher,

    Alan Branson here with We conduct business in all 50 states. What type of business do you have? provides funding for all types of businesses. There is no collateral required and funding is usually approved within 3-5 business days.

  • The depth of the information about this topic is being assessed, and there must be accountability for those who have been involved in this subterfuge.

    Hopefully, we will sooner than later be reading the outcome of the individual who were in collusion with the activities of what has to be addressed in a court of law, at least.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy